MFHAX Rating, Research - Munder Healthcare A

Munder Healthcare A (mfhax)

Last Updated by WikiWealth | Update This Page Now

►Summary | Add New Mutual Fund | Feedback

Short Term Rating Stock Ratings Help

Asset Allocation (% of Port)

US Stocks
Non-US Stocks

Geographic Allocation (% of Port)

North America
South America
Australia + Pacific Islands
Long Term Rating Stock Ratings Help


SWOT Statistics

Strengths + Opportunities = 66

Threats + Weaknesses = 45

When strengths & opportunities substantially exceed threats & weaknesses an investment in the mfhax mutual fund has great long term potential.

Fund Management Team

Fund Description Update

Munder Healthcare A (MFHAX) Description: MFHAX is a mutual fund, which is an investment that owns a basket of assets. The MFHAX mutual fund was provided by Munder and this investment vehicle derives the majority of its value from equity holdings (stocks). Munders mutual fund has a short management tenure and is in the small fund size classification. MFHAXs minimum initial investment amount is $2500 while the IRA minimum is $500. MFHAXs expense ratio is roughly 2%. The latest MFHAXs front end load was 6% and the back end load was 0%. The Munder Healthcare A (MFHAX) mutual fund falls under the health category. MFHAX focuses its investments in USA and MFHAX is focused on the health industry or fund sector. The Munder Healthcare A (MFHAX) mutual fund is not a leveraged fund and it does not have inverse fund properties. An investor can find MFHAXs top holdings, fundamental analysis, ratings, and fund risk (volatility) on the left side of the screen. The right side of MFHAXs research report features technical analysis and long term investment potential.

Portfolio Strategy Update

This investment vehicle seeks long-term capital appreciation. The fund normally invests at least 80% of assets in health care companies, which are companies for which at least 50% of sales, earnings or assets arise from or are dedicated to health or medical-related activities. Healthcare companies include drug and drug delivery companies; biotechnology firms; medical device and instrument manufacturers; and health care services companies, including HMOs, hospitals, product distributors and clinical laboratories. The fund invests up to 25% of asset in foreign securities.

Management Analysis Update

Performance Analysis Update